
England's National Health Service (NHS) announced yesterday that it is expanding its subscription-style payment model for antibiotics.
Under a pilot program launched in June 2022, NHS England awarded subscription contracts of up to £10 million a year (US $12.9 million) for 10 years for access to cefiderocol and ceftazidime-avibactam, manufactured by Shionogi and Pfizer, respectively. The idea behind the program was to provide the companies with a fixed annual fee based on the value of the antibiotics to the NHS and patients, rather than the volumes sold, and remove any incentive to overuse the drugs while incentivizing companies to develop new antibiotics.
With the proposed expansion of the program, the annual contracts could double to £20 million (US $25.9 million), based on criteria developed by the National Institute for Health and Care Excellence, and all UK nations will have access to the antibiotics.
The development of new antibiotics is absolutely essential to help build resilience to respond rapidly to new superbugs and save lives.
"As we continue to take lessons from the COVID-19 pandemic, the development of new antibiotics is absolutely essential to help build resilience to respond rapidly to new superbugs and save lives," David Glover, NHS assistant director of medicines analysis, said in an NHS press release. "With the proposed expansion of our world-first subscription model following a successful pilot, we want to meet this challenge head on and lead the response to the global battle against antimicrobial resistance, which could undermine the ability to deliver routine hospital care and treatment for patients."
A 12-week consultation will seek input from the pharmaceutical industry, patients, healthcare providers, and academics. Proposals will prioritize products that are active against pathogens deemed by the World Health Organization to be the most urgent threats.